Prof Andrzej Jakubowiak speaks to ecancer at virtual ASH 2020 about the initial analysis of safety data from the phase II ASCENT trial which evaluated induction, consolidation and maintenance in subjects with high risk smouldering MM.
He explains that currently smouldering MM is observed without therapy but, as it can be at a high risk of progression, this study explored whether more intensive intervention at this stage could potentially eliminate the disease.
Prof Jakubowiak explains that in this safety report the tolerability was expected compared to similar studies such as the Forte trial and the conclusion was that the regimen had been well tolerated.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.